Clinical Trials
60 trialsKeyPemls-004
Peking Union Medical College Hospital
Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy
The First Affiliated Hospital of Xinxiang Medical College
Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Beijing Biostar Pharmaceuticals Co., Ltd.
A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields (EFE-P100)Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1(PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
SABRE
Wuhan University
A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer
Shandong Cancer Hospital and Institute
A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients
Shandong Cancer Hospital and Institute
EPIC
University of Turin, Italy
DOMINUS
Biocad
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
OITROLC
Sichuan Cancer Hospital and Research Institute
Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer
Hunan Cancer Hospital
A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC
Peking University Cancer Hospital & Institute
ACWDVDFPTAN
Sir Run Run Shaw Hospital
ALTER-L024
China Medical University, China
ACDFNSNSCLC
Qilu Hospital of Shandong University
ACDFNSCLC
The Affiliated Hospital of Qingdao University
A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients
Haining Health-Coming Biotech Co., Ltd.
Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC
First Affiliated Hospital of Guangxi Medical University
M14AFS
The Netherlands Cancer Institute
An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study
SciClone Pharmaceuticals
Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer
Oshadi Drug Administration
Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer
The Cooper Health System
Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC
Peking University People's Hospital
Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors
National University Hospital, Singapore
Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
TCL-1
Qilu Hospital of Shandong University
Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC
Fudan University
Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer
Guangdong Association of Clinical Trials
Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment
Betta Pharmaceuticals Co., Ltd.
BRAVO
Tongji University
Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer
Shandong Cancer Hospital and Institute
Oncology
National Taiwan University Hospital
Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in Phaseâ… B
Xinjiang Medical University
Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC
Peking Union Medical College Hospital
Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy
Peking Union Medical College Hospital
TAILOR
Fatebenefratelli and Ophthalmic Hospital
A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment
Korean South West Oncology Group
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients
Fudan University